We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
An Earnings Beat: Phillips 66 (PSX - Free Report) reported second quarter income per share of $2.80, higher than the Zacks Consensus Estimate of $2.16. Higher segment earnings from all segments contributed to the growth.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate has seen no revisions in the last seven days.
Nonetheless, Phillips 66 has an impressive earnings surprise history. Before posting the earnings beat in Q2, the company delivered positive surprises in all of the prior four quarters. Overall, the company has a positive earnings surprise of 14.3% in the trailing four quarters.
Revenues: Phillips 66 posted revenues of $29.7 million, beating the Zacks Consensus Estimate of $29.4 million. It also increased from the year-ago number of $24.6 million.
Key Stats: The Midstream segment posted quarterly income of $202 million, compared to $96 million in the year-ago quarter. The Chemicals segment reported earnings of $262 million as against $196 million in the year-earlier quarter. The Refining segment posted quarterly income of $910 million compared to $224 million in the prior-year quarter. This Marketing and Specialties segment recorded earnings of $237 million compared with $214 million in the year-ago quarter.
Zacks Rank: Currently, Phillips 66 carries a Zacks Rank #2 (Buy) which is subject to change following the earnings announcement. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
Check back later for our full write up on this Valero earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Phillips 66 (PSX) Surpasses Q2 Earnings & Revenue Estimates
An Earnings Beat: Phillips 66 (PSX - Free Report) reported second quarter income per share of $2.80, higher than the Zacks Consensus Estimate of $2.16. Higher segment earnings from all segments contributed to the growth.
Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate has seen no revisions in the last seven days.
Phillips 66 Price and EPS Surprise
Phillips 66 Price and EPS Surprise | Phillips 66 Quote
Nonetheless, Phillips 66 has an impressive earnings surprise history. Before posting the earnings beat in Q2, the company delivered positive surprises in all of the prior four quarters. Overall, the company has a positive earnings surprise of 14.3% in the trailing four quarters.
Revenues: Phillips 66 posted revenues of $29.7 million, beating the Zacks Consensus Estimate of $29.4 million. It also increased from the year-ago number of $24.6 million.
Key Stats: The Midstream segment posted quarterly income of $202 million, compared to $96 million in the year-ago quarter. The Chemicals segment reported earnings of $262 million as against $196 million in the year-earlier quarter. The Refining segment posted quarterly income of $910 million compared to $224 million in the prior-year quarter. This Marketing and Specialties segment recorded earnings of $237 million compared with $214 million in the year-ago quarter.
Zacks Rank: Currently, Phillips 66 carries a Zacks Rank #2 (Buy) which is subject to change following the earnings announcement. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank stocks here)
Check back later for our full write up on this Valero earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>